PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Usefulness of 18F-FDG PET/CT for evaluating response of ocular adnexal lymphoma to treatment.

Abstract The purpose of this study was to investigate the efficacy of F-fluoro-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for evaluating the ocular adnexal lymphoma treatment responses.We retrospectively reviewed data for 9 histologically confirmed cases of malignant lymphoma. All patients had at least one ocular adnexal tumor site and underwent FDG PET/CT before and after treatment. Patients' histological disease subtypes included diffuse large B-cell lymphoma (n = 3), mucosa-associated lymphoid tissue lymphoma (n = 2), follicular lymphoma (n = 1), NK/T-cell lymphoma (n = 1), lymphoplasmacytic lymphoma (n = 1), and Hodgkin lymphoma (n = 1). The highest FDG uptake by the ocular adnexal lesions was calculated as the maximum standardized uptake value (SUVmax). FDG uptake at ocular adnexal sites and sites of systemic disease after treatment were also assessed using the 5-point Deauville scale.In 1 of the 9 patients, a conjunctival lesion could not be detected by either pre- or posttreatment PET/CT. For 8 of the 9 patients, the SUVmax value at the ocular adnexal site significantly decreased after treatment (7.1 ± 5.1 vs 1.6 ± 0.58; P = .0196). For 7 of the 9 patients, the first posttreatment FDG uptake at the ocular adnexal site was considered a complete metabolic response, and these patients showed an improved clinical ophthalmic presentation with no relapse at ocular adnexal sites during follow-up.FDG PET/CT is useful for evaluation of the response of ocular adnexal lymphoma to treatment, although its usefulness may depend on the histological subtype and site of the lesion.
PMID
Related Publications

Prognostic value of SUVmax measured by pretreatment 18F-FDG PET/CT in patients with primary gastric lymphoma.

Value of 18FDG PET scan in staging of ocular adnexal lymphomas: a large single-center experience.

The Role of FDG-PET in the Diagnosis and Staging of Ocular Adnexal Lymphoproliferative Disease.

Value of positron emission tomography in staging ocular adnexal lymphomas and evaluating their response to therapy.

Positron emission tomography in the detection and staging of ocular adnexal lymphoproliferative disease.

Authors

Mayor MeshTerms

Fluorodeoxyglucose F18

Positron Emission Tomography Computed Tomography

Radiopharmaceuticals

Keywords
Journal Title medicine
Publication Year Start




PMID- 29703034
OWN - NLM
STAT- MEDLINE
DCOM- 20180507
LR  - 20180507
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 17
DP  - 2018 Apr
TI  - Usefulness of 18F-FDG PET/CT for evaluating response of ocular adnexal lymphoma
      to treatment.
PG  - e0543
LID - 10.1097/MD.0000000000010543 [doi]
AB  - The purpose of this study was to investigate the efficacy of
      F-fluoro-deoxyglucose (FDG) positron emission tomography/computed tomography
      (PET/CT) for evaluating the ocular adnexal lymphoma treatment responses.We
      retrospectively reviewed data for 9 histologically confirmed cases of malignant
      lymphoma. All patients had at least one ocular adnexal tumor site and underwent
      FDG PET/CT before and after treatment. Patients' histological disease subtypes
      included diffuse large B-cell lymphoma (n = 3), mucosa-associated lymphoid tissue
      lymphoma (n = 2), follicular lymphoma (n = 1), NK/T-cell lymphoma (n = 1),
      lymphoplasmacytic lymphoma (n = 1), and Hodgkin lymphoma (n = 1). The highest FDG
      uptake by the ocular adnexal lesions was calculated as the maximum standardized
      uptake value (SUVmax). FDG uptake at ocular adnexal sites and sites of systemic
      disease after treatment were also assessed using the 5-point Deauville scale.In 1
      of the 9 patients, a conjunctival lesion could not be detected by either pre- or 
      posttreatment PET/CT. For 8 of the 9 patients, the SUVmax value at the ocular
      adnexal site significantly decreased after treatment (7.1 +/- 5.1 vs 1.6 +/-
      0.58; P = .0196). For 7 of the 9 patients, the first posttreatment FDG uptake at 
      the ocular adnexal site was considered a complete metabolic response, and these
      patients showed an improved clinical ophthalmic presentation with no relapse at
      ocular adnexal sites during follow-up.FDG PET/CT is useful for evaluation of the 
      response of ocular adnexal lymphoma to treatment, although its usefulness may
      depend on the histological subtype and site of the lesion.
FAU - Fujii, Hayahiko
AU  - Fujii H
AD  - Department of Radiology.
FAU - Tanaka, Hiroaki
AU  - Tanaka H
AD  - Department of Hematology.
FAU - Nomoto, Yohei
AU  - Nomoto Y
AD  - Department of Ophthalmology.
FAU - Harata, Naoki
AU  - Harata N
AD  - Department of Radiology.
FAU - Oota, Sayako
AU  - Oota S
AD  - Department of Radiology.
FAU - Isogai, Jun
AU  - Isogai J
AD  - Department of Radiology.
FAU - Yoshida, Katsuya
AU  - Yoshida K
AD  - PET Imaging Center, Asahi General Hospital, Asahi, Chiba, Japan.
LA  - eng
PT  - Evaluation Studies
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - AIM
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Eye Neoplasms/*diagnostic imaging/therapy
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/*diagnostic imaging/therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasms, Adnexal and Skin Appendage/*diagnostic imaging/therapy
MH  - Orbit/diagnostic imaging
MH  - Orbital Neoplasms/diagnostic imaging/therapy
MH  - *Positron Emission Tomography Computed Tomography
MH  - *Radiopharmaceuticals
MH  - Retrospective Studies
MH  - Treatment Outcome
EDAT- 2018/04/29 06:00
MHDA- 2018/05/08 06:00
CRDT- 2018/04/29 06:00
PHST- 2018/04/29 06:00 [entrez]
PHST- 2018/04/29 06:00 [pubmed]
PHST- 2018/05/08 06:00 [medline]
AID - 10.1097/MD.0000000000010543 [doi]
AID - 00005792-201804270-00066 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Apr;97(17):e0543. doi: 10.1097/MD.0000000000010543.